Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of DiviTum-TKa as a Biomarker Assay for CDK4/6 Inhibitor Medication Compliance and Drug-Drug Interaction Assessment in ER/PR Positive Metastatic Breast Cancer

NCT06572800 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT06572800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06572800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of DiviTum-TKa as a Biomarker Assay for CDK4/6 Inhibitor Medication Compliance and Drug-Drug Interaction Assessment in ER/PR Positive Metastatic Breast Cancer
Lead sponsor
Yale University
Phase
Not applicable
Overall status
Completed
Start date
September 5, 2023
Completion date
September 16, 2025
Enrollment
34 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, metastatic her2-negative breast carcinoma